[(2S)-2-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [(2S)-2-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate
• 化学式: C₃₇H₆₉O₈P
• 分子量: 672.9
• InChiKey: ABDVMXLJKAKVKI-DATDAJMQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.2
• 重原子数：
  46
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi
  申请人：Laing Susan T.

  公开号：US20080305156A1

  公开（公告）日：2008-12-11

  We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.

  我们披露了一种包含具有外表面、内表面和至少一个由饱和磷脂、不饱和磷脂、混合磷脂和胆固醇中至少一种脂质选择的超声造影脂质体（ELIP）的组合物，并且ELIP困住了一个溶栓化合物。我们还披露了一种治疗患有患者血管系统中血栓的医疗状况的方法，包括向患者投药该组合物，以有效减小血栓的大小。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARCOIDOSIS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE SARCOÏDOSE
  申请人：INSMED INC

  公开号：WO2017019636A1

  公开（公告）日：2017-02-02

  Compounds, methods, compositions and kits for treating a patient with pulmonary sarcoidosis are provided. The compositions are formulated for delivery to a patient in need of treatment via inhalation. In one embodiment, the method of treating pulmonary sarcoidosis in a patient in need thereof includes administering to the lungs of the patient via inhalation, a composition comprising an effective amount of a disease-modifying antisarcoid compound, a prodrug thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable inhalation excipient. The disease-modifying antisarcoid compound can be an immunomodulating agent, for example derivatives of mycophenolic acid, or a TNF-α antagonist.

  本发明提供了用于治疗肺结节病患者的化合物、方法、组合物和试剂盒。所述组合物经配制后可通过吸入途径给予需要治疗的患者。在一种实施例中，治疗肺结节病的方法包括通过吸入途径向患者的肺部给予一种组合物，所述组合物包括有效量的疾病修饰性抗结节病化合物、其前药或其药学上可接受的盐和药学上可接受的吸入助剂。疾病修饰性抗结节病化合物可以是免疫调节剂，例如麦考酚酸衍生物或TNF-α拮抗剂。
• Compositions and methods for treating transplants
  申请人：——

  公开号：US20040213766A1

  公开（公告）日：2004-10-28

  Methods and compositions for protecting transplants from immunorejection are provided.

  本发明提供了用于保护移植物免受免疫排斥的方法和组合物。
• Vaccines against diseases causing bacteria with capsular polysaccharides and process of preparing them
  申请人：Rijksuniversiteit Utrecht

  公开号：EP0097407A1

  公开（公告）日：1984-01-04

  Vaccines against pathogenic bacteria with capsular polysaccharides comprising oligosaccharides which are anchored in a liposome via amines, as well as a process for preparing such vaccines wherein capsular polysaccharides are hydrolyzed to oligosaccharides with 6-10 monosaccharide units, thereafter selected oligosaccharides with antigenic properties are reductively aminated and the obtained glycolipids are anchored in a liposome.

  使用由低聚糖组成的胶囊多糖抗病原菌疫苗，低聚糖通过胺锚定在脂质体中，以及制备这种疫苗的工艺，其中胶囊多糖被水解为具有 6-10 个单糖单位的低聚糖，然后将选定的具有抗原特性的低聚糖还原胺化，并将得到的糖脂锚定在脂质体中。
• Enzymatic production of phospholipid-saccharide derivatives
  申请人：MEITO SANGYO KABUSHIKI KAISHA

  公开号：EP0125039A2

  公开（公告）日：1984-11-14

  A process for producing a saccharide derivative of a phospholipid, which comprises reacting a phospholipid with a monosaccharide having 5 to 7 carbon atoms, at least one primary alcohol group and at least three hydroxyl groups in total including the OH of the primary alcohol group or a disaccharide thereof, said saccharide being optionally substituted by a group selected from the class consisting of amino and acetylamino groups, or a phenolglycoside of said saccharide the presence of phospholipase DM.

  一种生产磷脂糖衍生物的工艺，包括将磷脂与具有 5 至 7 个碳原子、至少一个伯醇基团和总共至少三个羟基（包括伯醇基团的羟基）的单糖或其二糖反应，所述糖可选择被选自氨基和乙酰氨基的基团或所述糖的酚糖苷取代。